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Introduction
Cationic lipidic formulations have recently become popular gene transfer reagents and have shown great promise as an alternative nonviral gene delivery vector for gene therapy. [1] [2] [3] However, the efficiency of lipidic vectors has to be improved before they can find broad clinical applications. 4, 5 Current efforts to improve the transfection efficiency of cationic liposomes are focused on the synthesis of new cationic lipids [6] [7] [8] and on the search for better lipidic formulations. [9] [10] [11] These approaches are largely based upon the study of structure-function relationships of cationic lipids and upon a better understanding about how liposome/DNA complexes (lipoplex 12 ) transfect cells in vitro. Little is understood about how cells are transfected in vivo. It is known that the in vivo performance of a lipidic vector depends on the administration route. A formulation suitable for intratracheal injection may not work when administered intravenously and vice versa. This might be due to the biological characteristics of different target cells. The biological environment, where the interaction between lipoplex and target cells takes place, also plays an important role. Understanding of the barriers for in vivo lipofection via different administration routes is, therefore, critical for the development of a suitable gene delivery vector.
Intravenous gene delivery via lipoplex was first reported by Zhu et al 13 in 1993 and has recently attracted increasing attention. 14 Several parameters have been identified to be important for achieving a high level of gene expression. For example, a high +/− charge ratio between a cationic lipid and DNA is important for efficient intravenous gene delivery. 15, 16 Also, multilamellar liposomes are more efficient than sonicated liposomes for in vivo gene transfer. 17 Furthermore, inclusion of cholesterol as a helper lipid greatly improves the transfection efficiency of lipoplex while DOPE significantly decreases its activity. [17] [18] [19] Now, it appears to be possible to achieve a high-level, reproducible transgene expression in various tissues via intravenous administration of lipoplex. However, little is known about how different liposomal formulations interact with serum components and the mechanism by which the lipoplex transfects cells in vivo. In a previous study, we demonstrated that the use of a cationic peptide such as protamine sulfate could improve the in vivo activity of lipoplex. 16 In this study, factors influencing the in vivo activity of LPD were further investigated. Interaction of mouse serum with LPD was also studied by analyzing changes in the physical characteristics of LPD and the serum proteins associated with the particles. Our result showed an inverse correlation between the in vivo activity of LPD and the amount of associated serum proteins, suggesting that incorporation of serum proteins into LPD might be a major factor limiting the efficiency of i.v. administered cationic lipidic vectors.
Results
Preparation and characterization of LPD Figure 1 shows the size of LPD formulations prepared by two different protocols. One involves the precomplexation of plasmid DNA with protamine sulfate followed by the addition of cationic liposomes as described previously. 16 The other involves the mixing of cationic liposomes with protamine sulfate before the addition of plasmid DNA. It can be seen that, with either protocol, protamine significantly reduced the size of lipoplex. However, the amount of protamine which can be used to prepare LPD is limited with the former protocol. Increasing the ratio of protamine/DNA (w/w) above 0.6 resulted in the formation of aggregates. Also, preparation of LPD became difficult when the respective concentration of protamine and DNA is high (data not shown). In contrast, with the new protocol, LPD of small size can be formed in a wider range of protamine/DNA ratios. The protamine/DNA ratio can be increased to 4/3 without the problem of aggregation. The new protocol was thus employed in all subsequent studies. Figure 2 shows the effect of helper lipids on the in vivo activity of LPD. Inclusion of DOPE into DOTAP liposomes significantly decreased the in vivo activity of LPD while the use of cholesterol greatly enhanced the transfection efficiency of LPD. Therefore, DOTAP:cholesterol liposomes were used to form LPD in all of the subsequent studies. Figure 3 shows the in vivo activity of LPD as a function of the dose of protamine. Inclusion of protamine could increase the transfection efficiency of DOTAP:cholesterol liposome/DNA complexes. At a protamine/DNA weight ratio of 0.6, the level of gene expression by LPD in lung, liver and heart was about five-to 10-fold higher than that of the corresponding lipoplex. Continuous increase in the dose of protamine sulfate was not associated with a further increase in the level of gene expression. Therefore, the protamine/DNA ratio of 0.6 was used to formulate LPD preparations. DOTAP liposomes significantly increased the in vivo activity of LPD especially when the dose of DOTAP lipid was low. Also, the use of cholesterol greatly decreased the amount of DOTAP lipid required to achieve a maximal level of gene expression. The optimal ratio between DOTAP and DNA was 12 nmol lipid per microgram DNA when DOTAP:cholesterol liposomes were used.
Based on the above studies, a protocol, in which extruded DOTAP:cholesterol liposomes were mixed with protamine sulfate before the addition of diluted plasmid DNA, was chosen to prepare LPD formulation. The optimal ratio in the LPD was 0.6 g protamine per microgram DNA per 12 nmol DOTAP. This LPD could give a dose-dependent gene expression in various tissues including heart, lung, liver, spleen and kidney with the highest level of gene expression in the lung ( Figure 5 ). The optimal dose was 50 g DNA per mouse. Increasing the dose to 100 g DNA per mouse resulted in noticeable toxicity (decreased locomotor activity, decreased sensitivity to touch, loss in body weight and piloerection) and sometimes death of the injected animals.
Role of free lipids in enhancing the in vivo activity of LPD It can be envisioned that at the optimal ratio of protamine/DNA/DOTAP:cholesterol liposomes, significant amounts of DOTAP:cholesterol liposomes would stay as free liposomes in the LPD preparations. This was confirmed in the sucrose gradient ultracentrifugation of LPD ( Figure 6a ). The amount of free liposomes increased with the increase in the amount of input protamine sulfate (data not shown). Indeed, when DNA was precomplexed with protamine at a ratio of 1/8 (w/w) and then mixed with liposomes, the protamine/DNA complexes and liposomes are completely separated from each other. 16 To test whether excess free liposomes are essen- tial for a high level of gene expression by LPD, the purified LPD was injected into mice and its activity was then compared with that of unpurified LPD. As shown in Figure 6b , removal of free lipids from LPD resulted in a significant reduction in the level of gene expression in several tissues examined. The in vivo activity of purified LPD, however, was fully recovered by adding appropriate amounts of free DOTAP:cholesterol liposomes to the purified LPD.
Effect of mouse serum on LPD Figure 7a shows the sucrose gradient ultracentrifugation profile of LPD exposed to mouse serum (67%, v/v). Comparison of Figure 7a with Figure 6a suggests a structure rearrangement process which involves the utilization of free lipids. Unlike untreated LPD which exhibits as a heterogeneous population, LPD exposed to serum forms a new complex which exhibits as a single band in a 30-20-10-0% discontinuous sucrose gradient. This band contains most of the input DNA and lipids. Injection of the purified complexes gave an activity similar to that of a regular LPD formulation as shown in Figure 7b . Again, the complexes containing cholesterol gave the highest level of gene expression while the complexes containing DOPE were barely active in vivo (Figure 7b ). The physical characteristics of the purified complexes are shown in Table 1 . It can be seen that all of the LPD formulations become negatively charged after exposure to mouse serum. There is no significant difference in zeta potential among the three formulations. The complexes containing cholesterol have significantly less total protein than those containing DOPE while there is no significant difference in the total amount of protein between the LPD containing cholesterol and the LPD containing no helper lipid. Data from Table 1 also suggest an increase in the size of LPD after exposure to mouse serum. It should be pointed out that the size of LPD underwent a dynamic change with time. Addition of the LPD into mouse serum resulted in an immediate, noticeable increase in turbidity. The turbidity of the mixture continued to increase with time for all of the three LPD formulations. The size of serum-exposed LPDs in Table 1 were obtained 30 s after the exposure of LPDs to mouse serum. Figure 8 shows the results of SDS-PAGE of LPD after exposure to mouse serum. LPDs were purified twice by sucrose gradient ultracentrifugation to eliminate any possible serum contamination. It is clear that the LPD containing DOPE had overall greater amounts of associated serum proteins. In addition, this LPD was enriched in a protein corresponding to serum albumin in molecular weight. The LPD containing cholesterol has the least mount of associated albumin. SDS-PAGE analysis of the samples obtained by pelleting serum-exposed LPD at 8000 g for 10 min showed a similar result to that of sucrose gradient-purified complexes (data not shown). 
Discussion
Our previous study has shown that the use of a natural cationic peptide, protamine sulfate, can improve the efficiency of intravenous gene delivery via cationic liposomes. 16 The protocol involves precomplexation of plasmid DNA with protamine sulfate followed by the addition of DOTAP liposomes. There are two disadvantages with this protocol. One of them is that large amounts of excess cationic lipids are required to achieve a maximal level of gene expression. Typically, a cationic lipid/DNA molar ratio of greater than 35 is necessary for an efficient in vivo transfection. 16 The other problem is the difficulty in preparing a concentrated sample. This is due to the overwhelming interaction of protamine sulfate with plasmid DNA which makes preparation of protamine/DNA complexes difficult at high concentrations, especially when a high protamine/DNA ratio (w/w) is required. To solve these problems, a new protocol has been developed in this study, where protamine LPDs composed of different lipid compositions were mixed with serum at 1:2 ratio (v/v) and the mixtures were subjected to a sucrosegradient ultracentrifugation as described in Materials and methods. The purified complexes were then analyzed for size, zeta potential and the concentration of associated serum proteins, respectively. *P Ͻ 0.05 (versus DOTAP/DOPE (n = 5)).
Figure 8 Identification of the proteins associated with LPD after exposure to mouse serum. LPD containing different lipid compositions were exposed to mouse serum and the fractions enriched in DNA were purified by sucrose-gradient ultracentrifugation as described in the legend to Figure 7. Equal amounts of LPD (10 g DNA) were then run on a 10% polyacrylamide gel. Shown in Figure are: molecular weight marker (a), LPD containing DOTAP liposomes (b), LPD containing DOTAP:cholesterol liposomes (c), LPD containing DOTAP:DOPE liposomes (d), and mouse serum (e) (0.2 l).
sulfate is mixed with DOTAP/cholesterol cationic liposomes followed by the addition of plasmid DNA. Due to the competition between cationic liposomes and protamine for the interaction with plasmid DNA, the strong interaction between protamine and DNA is greatly reduced. Under optimal conditions, LPD with a mean diameter of about 135 nm can be routinely prepared. Also, by using DOTAP/cholesterol liposomes instead of DOTAP liposomes for the preparation of LPD, the amount of cationic lipids required for maximal activity is greatly reduced. As shown in Figure 4 , the optimal dose of cationic lipid in the new protocol is three times less than that in the previous protocol.
Recently, McLean et al 20 demonstrated that i.v. administered lipoplex rapidly forms large aggregates inside the microvascular beds. The level of gene expression in an organ is proportionally related to the amount of uptake of lipoplex. Yet, it is not known how cells are transfected in vivo. Our results showed that LPD became negatively charged after exposure to mouse serum, suggesting that negatively charged particles are involved in the in vivo transfection of LPD via intravenous administration. This hypothesis is supported by the observation that a serumexposed, sucrose gradient purified LPD (which is negatively charged) can transfect cells in vivo as efficiently as the untreated LPD (Figure 7 ). More study on the structure of serum-treated LPD and its interactions with cells in vitro might help us better understand the mechanism of in vivo lipofection.
Choice of a helper lipid is an important factor in efficient gene delivery via cationic lipidic vectors. While an active DOSPA/DOPE/DNA complex was reported by Hofland et al, 21 DOPE was found in many other studies to decrease the activity of lipoplex significantly. [17] [18] [19] Our study with LPD (lipopolyplex 12 ) agrees with the latter studies. While the reason for the discrepancy is not clear at present, the dramatic difference in activity among LPDs of different lipid compositions raises the question of how different helper lipids affect the interaction of LPDs with blood components and eventually their transfection efficiency. This question was partially answered in this study by analyzing the serum proteins associated with LPD after its exposure to mouse serum. As shown in Table 1 and Figure 8 , LPD containing DOPE has the highest amount of associated serum proteins while LPD containing cholesterol has the least amount of serum proteins. Also clear from Figure 8 is that LPD containing DOPE is more enriched in a protein corresponding to serum albumin in molecular weight. Recruitment of a large amount of serum proteins by DOPE-containing LPD might be due to the fluid nature of its bilayer. DOPE is a lipid which contains a relatively small head group and two bulky fatty acyl chains which give the molecule an inverted cone shape. It is not favorable for the formation of a bilayer structure by itself under physiological conditions. DOPE can form a bilayer with other lipids such as DOTAP, however, the resulting liposomes are 935 relatively unstable and could undergo destabilization upon the changes in pH, ion strength and temperature. 22 Such an unstable bilayer structure would allow serum proteins to bind to and/or be incorporated into DOPEcontaining LPD efficiently. It has been shown that the association of serum proteins plays an important role in the clearance of liposomes from the circulation. 23, 24 Liposomes composed of different lipid compositions vary in the amounts of associated serum proteins. Liposomes coated with a large amount of total serum proteins are rapidly cleared by cells of the reticuloendothelial system (RES). 23, 24 Likewise, incorporation of serum proteins in the LPD may facilitate its removal from blood circulation by RES. This is supported by the study of Liu et al 17 in which the residence of cholesterol-containing lipoplex in the lung is much longer than that of DOPE-containing lipoplex. Also, serum proteins such as albumin are able to release the DNA from polyplex containing polylysine. 25 The efficient interaction between the DOPE-containing formulations with serum proteins such as albumin would facilitate the process of DNA release, rendering the DNA more susceptible to enzymatic digestion in vivo. Taken together, these factors lead to reduced interaction of intact DNA with target cells (endothelial cells), resulting in a low level of gene expression in vivo. The enhancement of in vivo transfection by cholesterol may be largely due to its ability to stabilize the bilayer of LPD particles, which could reduce the amount of hostile serum components that can be incorporated into LPD particles. LPD containing DOTAP liposomes has an intermediate amount of associated serum proteins. This LPD was less efficient than that containing DOTAP/ cholesterol liposomes when the dose of DOTAP lipid was low. However, its activity can be significantly enhanced by increasing the amount of DOTAP lipid. One possible explanation is that an excess amount of free liposomes helps to neutralize the hostile components in the serum allowing the formation of an active complex that has a lesser amount of associated serum proteins and, therefore, is efficient in transfecting cells in vivo. This is supported by the study of Oja et al 23 in which the amount of serum proteins per mole of lipid (egg phosphatidylcholine/dioleoylphosphatidic acid/cholesterol) decreased with the increase of lipid dose administered. The hypothesis is further supported by our previous study where the half-life of LPD in the lung increased significantly with the increasing amount of cationic lipid. 16 In summary, a novel lipidic vector composed of DOT-AP:cholesterol liposomes, protamine sulfate and plasmid DNA has been developed, which can give a high level of gene expression upon intravenous administration. Studies on the interactions between mouse serum and LPD showed that LPD became negatively charged after its exposure to serum, suggesting that the mechanism of intravenous gene delivery via cationic lipidic vectors is different from that of in vitro lipofection. LPDs composed of different lipid compositions differ in the amount of serum proteins incorporated into the particles. Further studies on the numerous interactions with blood components and better understanding of the mechanism of in vivo lipofection will help to develop a more effective and target-specific delivery system for DNA. Purification and iodination of plasmid DNA Plasmid pCMVL, which contains the cDNA of firefly luciferase driven by a human cytomegalovirus immediate-early promoter, was amplified in DH5␣ strain of E. coli, isolated by alkaline lysis and purified by cesium chloride centrifugation. 26 Plasmid DNA was labeled with 125 I by using a published method 27 and purified by a spin column (Bio-Spin-P30; Bio-Rad, Hercules, CA, USA). The purified 125 I-labeled DNA contained roughly equal amounts of supercoiled and relaxed closed circular DNA, as examined by gel electrophoresis and autoradiography.
Preparation of liposomes
Liposomes containing DOTAP alone or in a 1:1 molar ratio with cholesterol or DOPE were prepared as follows. The lipid mixture in chloroform was dried as a thin layer in a 100-ml round-bottomed flask which was further dried under vacuum for 2 h. The lipid film was hydrated in 5% dextrose in water (D5W) to give a final concentration of 10 mg DOTAP/ml. Preparation of SUV by extrusion was performed according to the method described by Templeton et al. 19 The lipid solution was briefly sonicated, followed by incubation at 50°C for 10 min and then sequentially extruded through polycarbonate membranes with the following pore sizes: 1.0, 0.6, 0.2 and 0.1 m. Similarly, liposomes containing 3 H-DPPC were prepared with a specific activity of 70 nCi/mol lipid.
Preparation of LPD and DOTAP/DNA complexes For preparation of LPD, various amounts of DOTAP:cholesterol liposomes and protamine sulfate were mixed together before the addition of DNA. The mixture was allowed to stand at room temperature for 10 min before use. Similarly, LPD containing DOTAP liposomes or DOTAP:DOPE liposomes were prepared. For preparation of lipoplex, DNA was added to liposomes and the mixture was incubated at room temperature for 10 min before use. The size of LPD and lipoplex was measured by dynamic laser scattering using a Coulter N4SD particle sizer (Hialeah, FL, USA).
Assay for luciferase activity Female CD-1 mice of 4-6 weeks of age were used. They were purchased from Charles River Laboratories (Wilmington, MA, USA) and were housed in accordance with institutional guidelines. Individual mice in groups of five were injected via tail vein with 50 g of DNA complexed with liposomes or formulated in LPD in a total volume of 200 l 5% w/v glucose. Twenty-four hours following i.v. injection, the mice were bled from retro-orbital sinuses under anesthesia and were then killed by cervical dislocation. Heart, lung, spleen, liver and kidney were collected and washed with cold saline twice. The organs were homogenized with lysis buffer (0.05% Triton X-100, 2 mm EDTA, 0.1 m Tris, pH 7.8) using a tissue tearer (Biospec Products, Bartlesville, OK, USA). After two cycles of freeze and thaw, the homogenates were centrifuged at 14 000 g for 10 min at 4°C and 20 l of the supernatant was analyzed for luciferase activity using an Automated LB 953 luminometer equipped with an automated injector (Berthod, Bad Wildbad, Germany). The result was expressed as the relative light units per milligram of tissue protein.
Purification of LPD before and after exposure to mouse serum LPD was prepared as described above. Trace amounts of 125 I-labeled DNA and 3 H-labeled DOTAP:cholesterol liposomes were included for quantification. LPD was mixed with 50% sucrose to a final concentration of 30% and the resulting mixture was loaded to a 4.5 ml ultracentrifuge tube. One milliliter of sucrose solution of decreasing concentrations was then sequentially overlaid to form a 30-20-10-0% discontinuous gradient. The sample was centrifuged at 100 000 g at 20°C for 45 min in a SW50.1 rotor. Fractions were collected from top to bottom of the gradient. Both DNA and lipid contents were calculated for each fraction on the basis of radioactivity. The fractions enriched in DNA were subjected to size and zeta potential analyses. To evaluate the effect of serum on the physical properties of LPD, LPD was mixed with mouse serum at a 1:2 (v/v) ratio. The LPD was then purified by sucrose gradient ultracentrifugation twice and analyzed again for its size and zeta potential. The amount of total protein in LPD was measured using a BCA assay (Pierce, Rockford, IL, USA) after delipidation of samples. 28 The serum proteins associated with LPD were further analyzed by SDS-PAGE.
Zeta potential analysis
The analysis of the charge on the LPD was performed by examining its zeta potential with a ZetaSizer 4 (Malvern Instruments, Southborough, MA, USA). The system was calibrated using a −50 mV standard (DTS 50/50 Standard; Malvern Instruments) as recommended by the manufacturer. Experimental samples (3 ml) were measured six times for 30 s at 1000 Hz with zero field correction.
SDS-PAGE analyses
LPD containing DOTAP liposomes, DOTAP:cholesterol liposomes or DOTAP:DOPE liposomes were analyzed for their interactions with serum proteins. After sucrose gradient purification, equal amounts of LPD (10 g DNA) were run on a 10% polyacrylamide gel. In a separate experiment, LPDs of different lipid compositions were mixed with mouse serum, respectively, and then subjected to centrifugation at 8000 g for 10 min. The pellets were washed twice with PBS and then resuspended using 1% SDS and then analyzed by SDS-PAGE as described above.
Statistical analyses
The paired Student's t test was used to assess the level of significance between experimental groups.
